Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

Inclusion Criteria:

• De novo multiple myeloma
• ECOG 0-2
• No serious co-morbid illnesses and adequate organ function
• > 4 weeks from systemic steroids

Exclusion Criteria:

• No existing secondary malignancies and no history of secondary malignancies in the past 5 years
• No active autoimmune disease